Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Next-generation sequencing (NGS) is the technology of choice for the routine screening of tumor samples in clinical practice. In this setting, the targeted sequencing of a restricted number of clinically relevant genes represents the most practical option when looking for genetic variants associated...

Full description

Bibliographic Details
Main Authors:	Martina Dameri, Lorenzo Ferrando, Gabriella Cirmena, Claudio Vernieri, Giancarlo Pruneri, Alberto Ballestrero, Gabriele Zoppoli
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	International Journal of Molecular Sciences
Subjects:	next-generation sequencing multi-gene testing gene panels breast cancer metastatic triple-negative breast cancer tumor mutational burden
Online Access:	https://www.mdpi.com/1422-0067/22/13/7154

Similar Items

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)

EXTENDED PROGRESSION-FREE SURVIVAL ON FIRST LINE TREATMENT WITH DOCETAXEL IN PATIENT WITH METASTATIC TRIPLE NEGATIVE BREAST CARCINOMA
by: Sharma, Purva, et al.
Published: (2021)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01)

NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of <i>BRCA</i>-Negative Cases
by: Maria Zanti, et al.
Published: (2020-10-01)

DECODING THE TRANSCRIPTIONAL LANDSCAPE OF TRIPLE-NEGATIVE BREAST CANCER USING NEXT GENERATION WHOLE TRANSCRIPTOME SEQUENCING
by: Radovich, Milan
Published: (2012)

Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria
by: Juliane Hoyer, et al.
Published: (2018-09-01)

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers
by: Jongchan Kim
Published: (2021-06-01)

Study of the Genetic Variants in <i>BRCA1/2</i> and Non-<i>BRCA</i> Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina
by: Angela R. Solano, et al.
Published: (2021-05-01)

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
by: Borker Rohit, et al.
Published: (2011-06-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020-05-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
by: Alberto Montero, et al.
Published: (2012-12-01)

Whole Genome Transcriptome Analysis of the Association between Obesity and Triple-Negative Breast Cancer in Caucasian Women
by: Tarun K. K. Mamidi, et al.
Published: (2018-10-01)

Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
by: Salah Mabrouk Khallaf, et al.
Published: (2020-04-01)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
by: Mingxi Lin, et al.
Published: (2020-11-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
by: M. A. Frolova, et al.
Published: (2020-07-01)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
by: Joyce O’Shaughnessy, et al.
Published: (2021-07-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity
by: Ishita Gupta, et al.
Published: (2019-03-01)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
by: Liu MC, et al.
Published: (2019-12-01)

Triple-Negative Breast Cancer: One Or More Entities?
by: Matikas Alexios, et al.
Published: (2014-12-01)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
by: Lei L, et al.
Published: (2019-04-01)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
by: Mashan L. Abdullah, et al.
Published: (2018-12-01)

Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer
by: Melissa Quintero, et al.
Published: (2017-11-01)

Burden of early, advanced and metastatic breast cancer in The Netherlands
by: G. T. Vondeling, et al.
Published: (2018-03-01)

Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer
by: Jiande Wu, et al.
Published: (2019-10-01)

Beyond <i>BRCA1</i> and <i>BRCA2</i>: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
by: Aldo Germani, et al.
Published: (2020-09-01)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
by: Qi Zhao, et al.
Published: (2021-06-01)

Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype
by: Soumaya Allouch, et al.
Published: (2020-12-01)

Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis
by: Li L, et al.
Published: (2021-03-01)

INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer
by: Hugo Veyssière, et al.
Published: (2021-06-01)

Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
by: Davide Angeli, et al.
Published: (2020-02-01)

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
by: A. C. Picornell, et al.
Published: (2019-06-01)

The role and function of SOX11 in DNA damage in triple-negative breast cancer
by: Lee, Tian Yu
Published: (2019)

Intramedullary rod failure in metastatic breast cancer: Do triple negative cancer patients have more revision surgery?
by: Ana C. Belzarena, et al.
Published: (2021-06-01)

Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
by: Marta Vaz Batista, et al.
Published: (2021-08-01)

Metastatic breast cancer patient perceptions of somatic tumor genomic testing
by: Elizabeth J. Adams, et al.
Published: (2020-05-01)